A New Hope for Patients Lacking Suitable Stem Cell Donors Introduction Blood cancers such as leukemia, lymphoma, myelodysplastic syndromes, and multiple myeloma continue to challenge physicians worldwide. In many cases, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment option. However, for patients who do not have a matched donor, access to life-saving therapy is extremely limited. In 2025, a new breakthrough therapy named Zemcelpro has emerged as …